1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Skelton, N.J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Biochemistry
BICHAW
0033
0006-2960
42
9324
9334
10.1021/bi034386c
12899619
Complex with a Phage Display-Derived Peptide Provides Insight into the Function of Insulin-like Growth Factor I
2003
UK
Chem.Biol.
CBOLE2
2050
1074-5521
9
495
506
10.1016/S1074-5521(02)00129-1
Rapid Identification of Small Binding Motifs with High-Throughput
Phage Display. Discovery of Peptidic Antagonists of Igf-1 Function
2002
10.2210/pdb1pmx/pdb
pdb_00001pmx
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
7663.752
Insulin-like growth factor IB
1
man
polymer
1879.216
IGF-1 ANTAGONIST F1-1
1
syn
polymer
IGF-IB, Somatomedin C
no
no
GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA
GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA
A
polypeptide(L)
no
no
RNCFESVAALRRCMYG
RNCFESVAALRRCMYG
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
Escherichia
sample
9606
Homo sapiens
562
Escherichia coli
43E7
plasmid
PBKIGF2B
database_2
pdbx_nmr_software
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
1
0
2003-10-21
1
1
2008-04-29
1
2
2011-07-13
1
3
2022-02-23
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_software.name
structure of free peptide igf-f1-1
RCSB
Y
RCSB
2003-06-11
REL
SEQUENCE DERIVED FROM PHAGE DISPLAY LIBRARY AND PREPARED BY CHEMICAL SYNTHESIS
sample
THE RESONANCE ASSIGNMENTS WERE DETERMINED USING TRIPLE-RESONANCE NMR SPECTROSCOPY.
LEAST VIOLATION OF EXPERIMENTAL RESTRAINTS
100
20
3D_15N-SEPARATED_NOESY
HNHA
D-HNHB
3D 15N-SEPARATED LOW MIXING TIME TOCSY
2D-15N-FILTERED NOESY
3D_13C-SEPARATED_NOESY
3D-13_FILTERED
13C-EDITED NOESY
2D-13C-FILTERED NOESY
25 mM
5.1
1
atm
313
K
THE COMPLEX WAS DETERMINED USING A TOTAL OF 905 NOE DISTANCE RESTRAINTS (146 INTRA RESIDUE, 203 SEQUENTIAL, 232 MEDIUM RANGE, 237 LONG-RANGE AND 87 INTERMOLECULAR), 24 HYDROGEN BOND RESTRAINTS, 139 DIHEDRAL ANGLE RESTRAINTS (72 PHI, 44 PSI AND 23 CHI-1). THE BEST 20 CONFORMERS (OF 100) HAD NO DISTANCE VIOLATIONS GREATER THAN 0.11A AND NO DIHEDRAL ANGLE VIOLATIONS GREATER THAN 1.5 DEGREES. RMSD FROM EXPERIMENTAL DISTANCE RESTRAINTS WAS 0.0049+/-0.0008. THE MEAN BACKBONE RMSD FROM THE MEAN STRUCTURE WAS 0.35 +/- 0.06 A FOR N, CA AND C ATOMS OF RESIDUES 3-26, 42-63 of IGF-I AND RESIDUES 3-15 OF THE PEPTIDE. 82% (17%) OF RESIDUES WERE IN THE MOST FAVOURED (ALLOWED) REGION OF PHI/PSI SPACE; NO RESIDUES WERE CONSISTENTLY IN THE DISALLOWED REGION.
TORSION ANGLE DYNAMICS, SIMULATED ANNEALING
1
closest to the average, fewest violations
1.4 MM IGF-I (15N), 2.0 MM PEPTIDE, 25 MM SODIUM ACETATE
1.4 MM IGF-I (13C,15N), 2.0 MM PEPTIDE, 25 MM SODIUM ACETATE
1.4 MM IGF-I (13C,15N), 2.0 MM PEPTIDE, 25 MM SODIUM ACETATE
D2O
ACCELRYS
refinement
CNS
2000.1
ACCELRYS
structure solution
XwinNMR
3.1
ACCELRYS
structure solution
Felix
98
600
Bruker
DRX
800
Bruker
DRX
GLY
1
n
1
GLY
1
A
PRO
2
n
2
PRO
2
A
GLU
3
n
3
GLU
3
A
THR
4
n
4
THR
4
A
LEU
5
n
5
LEU
5
A
CYS
6
n
6
CYS
6
A
GLY
7
n
7
GLY
7
A
ALA
8
n
8
ALA
8
A
GLU
9
n
9
GLU
9
A
LEU
10
n
10
LEU
10
A
VAL
11
n
11
VAL
11
A
ASP
12
n
12
ASP
12
A
ALA
13
n
13
ALA
13
A
LEU
14
n
14
LEU
14
A
GLN
15
n
15
GLN
15
A
PHE
16
n
16
PHE
16
A
VAL
17
n
17
VAL
17
A
CYS
18
n
18
CYS
18
A
GLY
19
n
19
GLY
19
A
ASP
20
n
20
ASP
20
A
ARG
21
n
21
ARG
21
A
GLY
22
n
22
GLY
22
A
PHE
23
n
23
PHE
23
A
TYR
24
n
24
TYR
24
A
PHE
25
n
25
PHE
25
A
ASN
26
n
26
ASN
26
A
LYS
27
n
27
LYS
27
A
PRO
28
n
28
PRO
28
A
THR
29
n
29
THR
29
A
GLY
30
n
30
GLY
30
A
TYR
31
n
31
TYR
31
A
GLY
32
n
32
GLY
32
A
SER
33
n
33
SER
33
A
SER
34
n
34
SER
34
A
SER
35
n
35
SER
35
A
ARG
36
n
36
ARG
36
A
ARG
37
n
37
ARG
37
A
ALA
38
n
38
ALA
38
A
PRO
39
n
39
PRO
39
A
GLN
40
n
40
GLN
40
A
THR
41
n
41
THR
41
A
GLY
42
n
42
GLY
42
A
ILE
43
n
43
ILE
43
A
VAL
44
n
44
VAL
44
A
ASP
45
n
45
ASP
45
A
GLU
46
n
46
GLU
46
A
CYS
47
n
47
CYS
47
A
CYS
48
n
48
CYS
48
A
PHE
49
n
49
PHE
49
A
ARG
50
n
50
ARG
50
A
SER
51
n
51
SER
51
A
CYS
52
n
52
CYS
52
A
ASP
53
n
53
ASP
53
A
LEU
54
n
54
LEU
54
A
ARG
55
n
55
ARG
55
A
ARG
56
n
56
ARG
56
A
LEU
57
n
57
LEU
57
A
GLU
58
n
58
GLU
58
A
MET
59
n
59
MET
59
A
TYR
60
n
60
TYR
60
A
CYS
61
n
61
CYS
61
A
ALA
62
n
62
ALA
62
A
PRO
63
n
63
PRO
63
A
LEU
64
n
64
LEU
64
A
LYS
65
n
65
LYS
65
A
PRO
66
n
66
PRO
66
A
ALA
67
n
67
ALA
67
A
LYS
68
n
68
LYS
68
A
SER
69
n
69
SER
69
A
ALA
70
n
70
ALA
70
A
ARG
101
n
1
ARG
101
B
ASN
102
n
2
ASN
102
B
CYS
103
n
3
CYS
103
B
PHE
104
n
4
PHE
104
B
GLU
105
n
5
GLU
105
B
SER
106
n
6
SER
106
B
VAL
107
n
7
VAL
107
B
ALA
108
n
8
ALA
108
B
ALA
109
n
9
ALA
109
B
LEU
110
n
10
LEU
110
B
ARG
111
n
11
ARG
111
B
ARG
112
n
12
ARG
112
B
CYS
113
n
13
CYS
113
B
MET
114
n
14
MET
114
B
TYR
115
n
15
TYR
115
B
GLY
116
n
16
GLY
116
B
author_defined_assembly
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
THR
29
-151.29
-47.15
1
A
SER
33
-150.06
-48.76
1
A
CYS
52
-105.49
-163.05
1
A
LEU
64
-58.34
170.95
1
A
PRO
66
-69.85
-169.18
2
A
PRO
2
-72.90
-168.80
2
A
THR
29
-172.58
-46.65
2
A
SER
34
-157.80
-56.39
2
A
THR
41
-177.56
127.77
2
A
LEU
64
-58.16
-179.73
2
A
ALA
67
-156.45
-68.00
2
B
PHE
104
-97.92
36.37
3
A
PHE
25
-59.23
-75.00
3
A
SER
34
-94.41
-65.24
3
A
ARG
36
-105.32
-68.92
3
A
ARG
37
-162.92
34.73
3
A
PRO
39
-73.33
-168.64
3
B
PHE
104
-94.63
46.57
4
A
THR
29
-164.42
32.22
4
A
SER
35
-148.80
-65.54
4
A
ALA
38
-168.94
-64.17
4
B
PHE
104
-96.52
32.84
5
A
PRO
2
-71.84
-168.71
5
A
SER
34
-147.55
-63.37
5
A
SER
35
-159.45
-74.83
5
A
LEU
64
-59.22
176.33
5
A
PRO
66
-61.47
83.21
5
A
ALA
67
-175.58
-176.21
6
A
ALA
67
-152.45
-51.89
6
A
LYS
68
-139.25
-48.16
6
A
SER
69
-158.72
32.73
6
B
PHE
104
-96.04
37.89
7
A
SER
34
-163.48
-65.45
7
A
PRO
39
-65.74
-168.17
7
A
ALA
67
-93.86
-70.99
8
A
SER
35
-153.50
33.40
8
A
PRO
39
-75.01
-168.83
8
B
PHE
104
-98.60
32.86
9
A
SER
34
-99.21
35.96
9
A
ALA
38
-174.75
94.88
9
A
PRO
66
-65.21
-167.80
9
B
PHE
104
-97.27
32.82
10
A
THR
29
-126.41
-58.08
10
A
SER
35
-91.35
-64.06
10
A
CYS
52
-111.77
-169.20
11
A
PRO
2
-90.25
43.53
11
A
THR
29
-179.20
-50.37
11
A
TYR
31
-148.57
-52.64
11
A
SER
34
-155.18
-70.67
11
A
SER
35
-170.17
34.69
11
A
ALA
38
-162.75
83.52
11
A
PRO
39
-79.21
-168.46
11
A
LEU
64
-59.97
178.82
11
A
ALA
67
-170.89
118.93
11
B
PHE
104
-97.87
35.80
12
A
THR
29
-160.04
115.17
12
A
ALA
38
-164.58
96.97
12
A
LEU
64
-55.94
179.44
12
B
PHE
104
-98.34
32.77
13
A
LYS
27
-67.63
-177.23
13
A
THR
29
-58.83
-75.48
13
A
ARG
36
-88.21
-70.93
13
A
CYS
52
-126.47
-160.47
14
A
TYR
31
-82.06
-73.06
14
A
SER
33
-149.30
-63.61
14
A
PRO
66
-66.97
-167.99
14
A
ALA
67
-81.52
-76.11
14
A
SER
69
-163.13
33.54
15
A
PHE
25
-57.32
-71.92
15
A
SER
33
-149.95
-55.37
15
A
ALA
38
-159.28
48.93
15
B
PHE
104
-98.64
32.74
16
A
PHE
25
-97.37
35.56
16
A
ASN
26
-176.36
126.12
16
A
ARG
37
-66.86
-168.84
16
A
CYS
52
-123.78
-160.86
16
A
ALA
67
-161.25
-53.41
16
A
LYS
68
-147.41
-47.64
16
B
PHE
104
-96.00
36.98
17
A
THR
29
-153.40
-54.32
17
A
SER
33
-149.27
-47.17
17
A
ARG
36
-54.30
89.39
17
A
LYS
68
-99.09
31.31
17
A
SER
69
-141.53
32.95
17
B
PHE
104
-97.68
33.19
18
A
PRO
2
-75.61
-168.97
18
A
ALA
38
-115.88
73.78
18
A
THR
41
-177.60
125.10
18
A
CYS
52
-123.32
-163.29
18
A
LEU
64
-59.98
174.40
18
A
LYS
68
-178.04
94.75
19
A
SER
33
-150.03
-54.44
19
A
CYS
52
-118.65
-164.47
19
A
ALA
67
-165.43
32.12
19
A
LYS
68
-101.93
-169.63
20
A
PRO
2
-73.46
-169.08
20
A
SER
35
-153.00
-64.41
20
A
ARG
36
-90.56
-60.21
20
A
ARG
37
-161.65
111.16
20
A
THR
41
-177.60
107.48
20
A
CYS
52
-117.00
-163.06
20
A
LEU
64
-58.31
173.27
20
B
PHE
104
-92.62
47.90
20
B
TYR
115
-69.13
71.17
INSULIN-LIKE GROWTH FACTOR-I BOUND TO A PHAGE-DERIVED PEPTIDE
1
N
N
2
N
N
A
GLY
7
A
GLY
7
HELX_P
A
CYS
18
A
CYS
18
1
1
12
A
GLY
19
A
GLY
19
HELX_P
A
GLY
22
A
GLY
22
5
2
4
A
ILE
43
A
ILE
43
HELX_P
A
CYS
48
A
CYS
48
1
3
6
A
ARG
55
A
ARG
55
HELX_P
A
CYS
61
A
CYS
61
1
4
7
B
SER
106
B
SER
6
HELX_P
B
TYR
115
B
TYR
15
1
5
10
disulf
2.031
A
CYS
6
A
SG
CYS
6
1_555
A
CYS
48
A
SG
CYS
48
1_555
disulf
2.031
A
CYS
18
A
SG
CYS
18
1_555
A
CYS
61
A
SG
CYS
61
1_555
disulf
2.029
A
CYS
47
A
SG
CYS
47
1_555
A
CYS
52
A
SG
CYS
52
1_555
disulf
2.030
B
CYS
103
B
SG
CYS
3
1_555
B
CYS
113
B
SG
CYS
13
1_555
HORMONE/GROWTH FACTOR
IGF-I, PEPTIDE BINDING, HIGH AFFINITY LIGAND, HORMONE-GROWTH FACTOR COMPLEX
IGF1B_HUMAN
UNP
1
49
P05019
GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA
1PMX
PDB
2
1PMX
49
118
1PMX
1
70
P05019
A
1
1
70
101
116
1PMX
101
116
1PMX
B
2
1
16